Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Early, ...

Please provide your email address to receive an email when new articles are posted on . In patients with primary progressive MS who experience persistent inflammatory activity, disease-modifying ...

Treatment of primary progressive multiple sclerosis (PPMS) with disease-modifying therapies (DMTs) for patients experiencing relapse or with disease activity is linked to a significant reduction of ...

A minority of patients with multiple sclerosis (MS) have primary progressive disease, and it has few treatment options. The challenges of developing treatments for primary progressive multiple ...

The post-hoc analyses found Ocrevus to significantly decrease disease activity and disability progression in patients with RMS and PPMS, as assessed by No Evidence of Progression or Active Disease ...

More than 80% of patients with multiple sclerosis (MS) have a relapsing-remitting (RRMS) course of the illness characterized by periods of neurologic symptoms followed by complete or partial recovery.

Tolebrutinib failed to meet the primary endpoint in the phase 3 PERSEUS study involving patients with primary progressive multiple sclerosis.

PARIS, France--(BUSINESS WIRE)--MedDay, a biotechnology company focused on the treatment of nervous system disorders, today announced positive results from the pivotal Phase III clinical trial, MS-SPI ...

Masitinib, an orally administered tyrosine kinase inhibitor targeting the innate immune system, showed positive signs in treating progressive forms of multiple sclerosis (MS) in the phase III AB07002 ...

Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis. PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint ...